MAT1A and metabolic dysfunction-associated steatotic liver disease: Here, we investigated if the pharmacological (antisense oligonucleotide (ASO) treatment) knockdown of the Mat1a gene, which is involved in the first reaction of the methionine cycle, provides beneficial outcomes in diet- and genetically- induced obesity and obesity-related NAFLD.